Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally.
about
High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literatureApolipoprotein E COG 133 mimetic peptide improves 5-fluorouracil-induced intestinal mucositis.Tomatoes, lysophosphatidic acid, and the small intestine: new pieces in the puzzle of apolipoprotein mimetic peptides?Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a reviewIn vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-I.The apolipoprotein-AI mimetic peptide L4F at a modest dose does not attenuate weight gain, inflammation, or atherosclerosis in LDLR-null mice.Apolipoprotein A-I mimetics.An apolipoprotein A-I mimetic peptide designed with a reductionist approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice.Enhancement by LDL of transfer of L-4F and oxidized lipids to HDL in C57BL/6J mice and human plasmaSource and role of intestinally derived lysophosphatidic acid in dyslipidemia and atherosclerosis.Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetesApolipoprotein A-I mimetic peptide 4F blocks sphingomyelinase-induced LDL aggregationD-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null miceHDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer.A novel approach to oral apoA-I mimetic therapyDysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteinsTg6F ameliorates the increase in oxidized phospholipids in the jejunum of mice fed unsaturated LysoPC or WD.HDL, Atherosclerosis, and Emerging TherapiesTransintestinal transport of the anti-inflammatory drug 4F and the modulation of transintestinal cholesterol effluxApolipoprotein A-1 mimetic D-4F enhances isoflurane-induced eNOS signaling and cardioprotection during acute hyperglycemia.Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acidMimicry of high-density lipoprotein: functional peptide-lipid nanoparticles based on multivalent peptide constructs.Arguing the case for the autotaxin-lysophosphatidic acid-lipid phosphate phosphatase 3-signaling nexus in the development and complications of atherosclerosis.Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis.Current guidelines for high-density lipoprotein cholesterol in therapy and future directions.Apolipoprotein A-I and A-I mimetic peptides: a role in atherosclerosisHigh-density lipoprotein mimetics: promises and challenges.Emerging Roles of Apolipoprotein E and Apolipoprotein A-I in the Pathogenesis and Treatment of Lung Disease.The potential of apolipoprotein mimetic peptides in the treatment of atherosclerosisTransgenic tomatoes expressing the 6F peptide and ezetimibe prevent diet-induced increases of IFN-β and cholesterol 25-hydroxylase in jejunum.Mimetic peptides of human apoA-I helix 10 get together to lower lipids and ameliorate atherosclerosis: is the action in the gut?Oral Apolipoprotein A-I Mimetic D-4F Lowers HDL-Inflammatory Index in High-Risk Patients: A First-in-Human Multiple-Dose, Randomized Controlled Trial.Apolipoprotein A-1 mimetic peptide 4F promotes endothelial repairing and compromises reendothelialization impaired by oxidized HDL through SR-B1.L-4F inhibits lipopolysaccharide-mediated activation of primary human neutrophils.Apolipoprotein A-I Mimetic Peptides: Discordance Between In Vitro and In Vivo Properties-Brief Report.Treating the Intestine with Oral ApoA-I Mimetic Tg6F Reduces Tumor Burden in Mouse Models of Metastatic Lung Cancer.
P2860
Q26996600-89772DCA-C080-4223-BE92-01E9205EFF09Q30425943-7BF5C3A5-F21A-4805-9C84-59D612485564Q33356762-C5A1E68E-8F05-4308-838B-ADA203F89EA7Q34238630-709571C7-F962-4B3F-9476-11D1273E2CCAQ34238652-DAF60CB9-2002-463E-BF1D-8C1C5BC83F3EQ34294433-98BB1610-42C5-49D9-A7BB-4EC0915BE337Q34421191-9B810858-04D2-4C0B-85D4-B92592FF6B78Q34851167-AA86BBD1-8E14-44B9-8D52-2A2F4A313002Q35212906-9A29F5BD-E6BE-4D15-ADE2-0F87B0D3F181Q35217048-1E3160CF-9701-4557-BF02-52474049601AQ35227165-F9E97F28-3D94-4559-ADFC-9277FCC788A8Q35642920-39E14252-D92B-49EA-99CA-6FE8C422B3E7Q35747768-B3496A66-E476-4444-89A4-831D818426A3Q36028380-6B1E9684-E452-4366-96C3-018D12D2D0EFQ36709656-D424380B-573E-4BB2-A4C9-214B6EE61436Q36763561-4FF4D1BF-C19B-4488-9E41-318446C7399AQ36843312-7BC9FC26-6FE4-47E9-A59B-17864F302329Q36918309-5FF5EEFF-25CF-4757-B55E-443CCA06123AQ37033119-E0637014-DCFC-48F6-A3C1-FD1B4D3F3D44Q37054501-E6C0B543-8D63-4322-9697-BC3BD3CFFDBEQ37305392-AC1B49A3-D03F-49FD-9233-86E02C905151Q37340299-662FE737-A983-4828-AC95-704DE0783629Q37620329-F67D2BE9-8D50-4BF5-ADCB-C22E1F5136DBQ37671683-6678ACF4-2DA4-47D9-89F9-4FB73E802996Q37702199-10485CA9-FA8F-4EDC-A840-221F0C2B0874Q37957869-ED5D0C15-46F9-4F6A-A5B6-E1AAC45EA3FDQ38650575-FBD714A9-594E-45BE-9974-08638E42993EQ38807248-18A13B8D-B287-4F4B-929A-A36FCC537A54Q40492051-5ECFC597-798E-4E5F-BFEF-A24AADFA0704Q42879444-1CF3D03B-6F31-461B-A982-274833A9407CQ42913663-4E5CF07F-2F74-4A2F-B568-6D9E23CB99F7Q46350113-1D19E321-5E90-4A43-B44E-0644636F7CBDQ49582789-F9B20BE5-426C-4252-A92A-4C56BDBA71F0Q50333030-A2DAA438-7057-467E-A20B-ADA042A0F810Q50993490-9DF41E30-E8DD-48F1-B601-953584F8F432Q55222132-3F2F67B8-6437-431B-A34A-A85BF81210C6
P2860
Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Intestine may be a major site ...... ered subcutaneously or orally.
@ast
Intestine may be a major site ...... ered subcutaneously or orally.
@en
Intestine may be a major site ...... ered subcutaneously or orally.
@nl
type
label
Intestine may be a major site ...... ered subcutaneously or orally.
@ast
Intestine may be a major site ...... ered subcutaneously or orally.
@en
Intestine may be a major site ...... ered subcutaneously or orally.
@nl
prefLabel
Intestine may be a major site ...... ered subcutaneously or orally.
@ast
Intestine may be a major site ...... ered subcutaneously or orally.
@en
Intestine may be a major site ...... ered subcutaneously or orally.
@nl
P2093
P2860
P356
P1476
Intestine may be a major site ...... ered subcutaneously or orally.
@en
P2093
Alan M Fogelman
G M Anantharamaiah
Greg Hough
Mohamad Navab
Satoshi Imaizumi
Srinivasa T Reddy
Susan Hama
P2860
P304
P356
10.1194/JLR.M013144
P577
2011-03-28T00:00:00Z